The Rockefeller University

The Picower Institute for Medical Research

Alteon Incorporated

The Kenneth S. Warren Institute, Inc.

Araim Pharmaceuticals, Inc.

Other

Evreka Inc.

Cytokine Pharmasciences, Inc.

Farrington Pharmaceuticals, Inc.

Cerami Consulting Corp.

Warren Pharmaceuticals, Inc.

Farington Pharmaceuticals, LLC

The Picowder Institute for Medical Research

Baxter International Inc.

Baxter Healthcare Sa

Anthony Cerami

Peter C Ulrich

Richard J Bucala

Helen Vlassara

Michael Brines

Stephen D Wolpe

Dilip R Wagle

Kevin J Tracey

Michael A Brownlee

Marina Bianchi

Bruce A Beutler

Michael I Bukrinsky

John J Egan

Sara Vasan

Carla Cerami

Barbara A Sherry

San-Bao Hwang

Thomas Coleman

Michael A Yamin

Robert A Mitchell

Jurgen Bernhagen

Thierry F Calandra

Henry W Founds

Masanobu Kawakami

Yong Ming Li

Taikyun Rho

Sheng-Ding Fang

Xini Zhang

Sheng Ding Fang

Zhi Yang

Graeme B Henderson

James G Farmar

Qiao-Wen Xie

Bradley Berger

Jean-Paul Wuerth

Sandor Pongor

Carla J Cerami

Yousef Al-Abed

Michael E Lankin

Michael Peter Vitek

David H Shih

Patricia A Tekamp-Olson

Yousef Al Abed

Osman Yilmaz

Thomas J Fahey, Iii

Annette T Lee

Dennis S France

Laura A Norton

David L Neer

Xini Xhang

Hauh-Jyun C Chen

Bradley J Berger

Farhad Imani

Ronald J Koenig

Michael L Bukrinsky

Penelope K Pettis

Jamshid Javid

Nina F Tabachnik

Peter Hotez

Klaus Bendrat

Provided herein are peptides and peptide analogs that have tissue protective activities. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.

Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor. The invention is further directed to the consensus sequences for use in engineering a synthetic tissue protective peptide. These tissue protective peptides also include fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO. The invention further encompasses methods for treating or preventing a disease or disorder using tissue protective peptides of the current invention. The invention also encompasses methods for enhancing excitable tissue function using tissue protective peptides of the current invention.

Tissue protective peptides and uses thereof

The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoetic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.

Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.

Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides.

Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering a composition comprising a tissue protective cytokine of the invention and administering at least one anti-inflammatory or least one immunomodulatory agent.

Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.

Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs

The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one &#x3b2;Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat various conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.

Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds

A method of treating, preventing, delaying the onset, and/or reducing the effects of proinflammatory cytokines in conditions including, but not limited to, sepsis, adhesion formation, wounds, organ failure, chronic disease, general inflammatory conditions resulting from infection, scarring resulting from injury and incisions, and combinations thereof.

Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions

The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.

Anti-MIF antibodies

Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.

Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin

A method and composition for the treatment of hair, nail, ex-vivo organ, ex-vivo cell or ex-vivo tissue to improve the biomechanical and diffusional characteristics comprising an effective amount of a compound selected from the group consisting of compounds of the formula (I): 

Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment

Growing community of inventors

Shelter Island, NY, United States of America

Anthony Cerami